OR WAIT null SECS
Patients with chronic inflammatory diseases, especially rheumatoid arthritis, are at 800% increased risk for developing Alzheimer disease compared to the general population. A new treatment is in the works to combat this inflammation.
Christopher J. Barnum, PhD, of INmune Bio, Inc discusses XPro1595, developed by INmune Bio, and how it may provide neuroprotective benefits for those at risk of developing Alzheimer disease.
Rather than focusing on amyloid or tau clearing therapies like many that have come before, this treatment takes a unique approach to tackling neuroinflammation by selectively neutralizing soluble tumor necrosis factor (sTNF). This is a a “bad” cytokine that is elevated in many chronic neurodegenerative and neuroinflammatory conditions.
In addition to this video, Dr Barnum recommends watching this webinar to learn more.
Dr Barnum is the Director of Neuroscience at INmune Bio, Inc. Dr Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academia and industry, including Emory University, FPRT Bio, SonosBio, and most recently Takeda Pharmaceuticals. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Dr Barnum has been working with XPro1595 for more than a decade, first at Emory University with Dr Malú Tansey and subsequently as a consultant for FPRT Bio, Inc and INmune Bio, before joining INmune Bio full time in 2018. Dr Barnum’s research has been supported by NIH, The Michael J Fox Foundation, and the Alzheimer’s Association. He received his PhD in Neuroscience from Binghamton University.